China has been engaged in the R&D and manufacturing of semi-automatic coagulation analyzers for over a decade, and based on the data from the website of the NMPA, in 2024 and 2025 (as od 15 August), a total of 2 instruments from 2 manufacturers have obtained registration certificates...

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China. Latest news

The creation of nanoscale computers for use in precision health care has long been a dream of many scientists and health care providers. Now, the research paves the way for the construction of complex nanoscale computers for the prevention and treatment of cancer and other diseases.

Burning Rock Biotech reported on Tuesday morning that its third quarter revenues rose about 2 percent year over year.

Illumina and Genetic Alliance said on Tuesday that they are launching a new program to expand patient access to whole-genome sequencing around the world.

Roche has again been recognized as one of the most sustainable companies in the Pharmaceuticals index of the Dow Jones Sustainability Indices (DJSI). This is based on an in-depth analysis of economic, social and environmental performance.

On November 15, 2021, Vazyme Biotech Co., Ltd. (hereinafter referred to as "Vazyme") was listed on SSE STAR Market. Stock abbreviation: Vazyme, stock code: 688105. The issue price is 55 yuan/share, and the opening price is 74 yuan/share.

The US Food and Drug Administration on Monday released revised guidance on its regulatory priorities and policies for COVID-19 tests.

Siemens Healthineers (ETR:SHL) shares ticked up today on fourth-quarter results that topped the consensus sales forecast.

An artificial intelligence (AI)-based technology rapidly diagnoses rare disorders in critically ill children with high accuracy, according to a report by researchers from University of Utah (U Of U) Health, Fabric Genomics, and collaborators on a study led by Rady Children’s Hospital in San Diego.

DiaSorin said in Q3 it saw a strong recovery of non-COVID test sales including for latent tuberculosis and other infectious diseases as well as gastrointestinal infections.

On November 10, Wuhan Landing Med officially announced that it had completed the round-D financing of RMB 320 million, which was led by Ali Health and followed by Ether Capital.